SPY434.36-5.48 -1.25%
DIA342.89-0.92 -0.27%
IXIC13,543.08-312.05 -2.25%

BRIEF-Janssen Submits Biologics License Application To U.S. FDA Seeking Approval Of Teclistamab For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma

reuters.com · 12/29/2021 08:04
BRIEF-Janssen Submits Biologics License Application To U.S. FDA Seeking Approval Of Teclistamab For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma

- Johnson & Johnson JNJ:

  • JANSSEN SUBMITS BIOLOGICS LICENSE APPLICATION TO U.S. FDA SEEKING APPROVAL OF TECLISTAMAB FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

  • JANSSEN SUBMITS BIOLOGICS LICENSE APPLICATION TO U.S. FDA SEEKING APPROVAL OF TECLISTAMAB FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Source text for Eikon: ID:nPn5QYdRfa

Further company coverage: JNJ


((Reuters.Briefs@thomsonreuters.com;))